ARTICLE | Clinical News
Arixtra fondaparinux: Phase IV data
February 13, 2006 8:00 AM UTC
In the open-label, U.S. Phase IV FLEXTRA study in 2,046 patients, there was no significant difference seen in the incidence of symptomatic VE when the first dose of Arixtra was given 6-10 hours post-s...